Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II dose-finding study of Alpharadin (radium-223) in hormone-refractory prostate cancer with bone metastases
2005-003680-22Phase 2Completed
- Sponsor
- Algeta ASA
- Start
- Dec 2005
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Alpha Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of radium-223 dichloride in prostate cancer (PCa) (3 arms), sponsored by Algeta ASA. Primary endpoint: PSA response rate. Started Dec 2005; status: completed.
02
Drugs
radium-223 dichloride
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2005-003680-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-003680-22.